Overview On or about December 10, 2021, a vulnerability was disclosed in the Apache Log4J software, which is a common logging system used by many applications built on Java. The vulnerability is commonly known as “Log4Shell.” More information on this vulnerability is available at https://logging.apache.org/log4j/2.x/security.html. Leica Biosystems is evaluating our products to determine whether they are impacted by this vulnerability.   Product Status Product Status regarding Log4Shell Description Aperio AT2 Not Vulnerable Log4J is not used. Aperio AT2 DX Not Vulnerable Log4J is ..read more

by Chad Salinas, Vice President, AI and Machine Learning Artificial Intelligence is exponentially increasing its impact on healthcare. As deep learning is mastering computer vision tasks, its application to digital pathology is natural, with the promise of aiding in routine reporting and standardizing results across trials. 1 Physicians recognize the potential of AI in pathology, with one global survey documenting nearly 75% of respondents reporting interest or excitement in AI as a diagnostic tool to facilitate improvements in workflow efficiency and quality assurance in pathology.2 This find ..read more

Our Commitment to Compliance Leica Biosystems is on track to align its portfolio of instrumentation and consumables with the In Vitro Diagnostics Regulation (IVDR) that comes into effect May of 2022. This new EU legislation mandates significant changes to the previous In Vitro Diagnostics Directive. The new Regulation means that manufacturers of in vitro diagnostic medical devices must work with a notified body to ensure that their devices conform with applicable requirements by the deadline. Leica Biosystems manufactures certain in vitro diagnostic medical devices that fall into Class A, B an ..read more

体外診断用医薬品に関して下記厚生労働省の通知*に従い、本年7月31日の入荷検品を行った製品への添付文書の挿入を最後とし、8月1日以降の入荷検品を行った製品に関しては、添付文書は挿入いたしません。 製品に貼付されている法定ラベルのバーコードに「添文ナビ」アプリをあてがい添付文書の入手をよろしくお願いいたします。なお、医療機器は、当面添付文書を同梱いたしますが、「添文ナビ」アプリからもe-添付文書を閲覧することも可能です。 *: 「医薬品等の容器等に記載された符号を読み取ることで注意事項等情報が掲載されている機構のホームページを閲覧するスマートフォン等のアプリケーションについて」 （令和3年5月10 ..read more

VISTA, CA –June 17, 2021 – Leica Biosystems, the global leader in pathology workflow solutions, announced today that its Next Generation Aperio GT 450 DX scanner now supports DICOM imaging. Working closely in partnership with Leeds Teaching Hospital NHS as part of the National Pathology Imaging Co-operative (NPIC) program, Leica Biosystems has developed a DICOM implementation that is designed to meet the need of enterprise healthcare organizations to standardize their medical imaging protocols. “Standardisation and interoperability are vital for the successful adoption of digital technologies ..read more

Leica Biosystems, a global leader in pathology workflow solutions, becomes a diamond sponsor and announces the start of a collaboration with the European Society for Digital and Integrative Pathology (ESDIP) to promote digital pathology adoption across Europe. "Building bridges between industry and academia is essential to furthering the work of a scientific society. The European Society of Digital and Integrative Pathology is delighted to welcome Leica Biosystems, a longtime member of the European Congress on Digital Pathology, as our closest partner to advance digital and integrative patholo ..read more

NEW YORK, NY and VISTA, CALIF. – April 23, 2021 — Paige, a global leader in AI-based digital diagnostics, and Leica Biosystems, a globally recognized cancer diagnostics and workflow solution leader, today announced a strategic partnership to expand access to computational pathology products for clinical and translational research. The partnership brings Paige’s AI-enabled research software for tumor detection, grading and quantification to Leica Biosystems digital pathology platform in select countries throughout North America and Europe. The companies will collaborate to streamline and accele ..read more

IMAGINE THE POSSIBILITIES FOR YOUR CHROMOGENIC MULTIPLEX WITH LEICA BIOSYSTEMS AND CELL IDx To accelerate the discovery journey in cancer research, Leica Biosystems has partnered with Cell IDx, a technology leader in multiplexed cellular immunodiagnostics, developing highly sensitive and specific reagents for research and clinical immunohistochemistry to meet the needs of precision medicine. Cell IDx technology allows the automated detection of multiple markers on the BOND RX staining system. The technology uses primary antibodies from any species, employing a single antigen retrieval step tha ..read more

Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform Leica Biosystems, in partnership with Bio-Techne Corporation, announces the automation of RNAscope™ COVID-19 probes’ on BOND RX*, its staining platform, for research use only. Researchers now have the capability to automate their COVID-19 research protocols, reducing manual labor and turnaround time. “We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Mel ..read more

Leica Biosystems, a global leader in pathology workflow solutions, announced the European launch of its Aperio GT 450 DX digital pathology scanner. This next generation imaging system was unveiled at the highly successful Leica Biosystems Digital Pathology Virtual Summit and is already installed at the Centre of Excellence at Leeds Teaching Hospitals NHS Trust NHS, UK. During the summit, nearly 3,000 virtual attendees joined thought leaders from around the globe to hear about the latest topics and advances in digital pathology. The featured attraction: the Aperio GT 450 DX Scanner. Combining p ..read more